Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
December 04 2017 - 6:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced the
appointment of Heather Johnson as Regional Sales Director for the
Northeast Region, reporting to Gary Menichini, Aerie’s Vice
President of Sales. Ms. Johnson will direct the activities of the
Company’s district sales managers and territory managers in the
Northeastern region of the United States, focused on execution of
Aerie’s sales strategies. She previously held related positions at
Novartis.
In connection with her acceptance of the position as Regional
Sales Director for the Northeast Region, Ms. Johnson will receive
awards totaling 16,000 stock options. The stock options will vest
over 4 years, with 25% vesting on the first anniversary of the hire
date and the remainder vesting ratably on each of the subsequent 36
monthly anniversaries of the hire date. This award was made outside
of Aerie’s stockholder-approved equity incentive plan and was
approved by the Company’s independent directors as an inducement
material to Ms. Johnson entering into employment with the Company
in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this
public announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two current product candidates are
once-daily intraocular pressure lowering therapies with novel
mechanisms of action to treat patients with glaucoma or ocular
hypertension. The NDA (new drug application) for Rhopressa®
(netarsudil ophthalmic solution) 0.02% was submitted to the U.S.
Food and Drug Administration (FDA) in February 2017, and, in May
2017, the FDA set the PDUFA (Prescription Drug User Fee Act) goal
date for the completion of the FDA’s review of the Rhopressa® NDA
for February 28, 2018. Aerie’s second product candidate, RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is
a fixed dose combination of Rhopressa® and widely prescribed PGA
latanoprost, achieved its primary efficacy endpoint in two Phase 3
registration trials, named Mercury 1 and Mercury 2, and also
achieved successful 12-month safety and efficacy results in Mercury
1. The RoclatanTM NDA submission is expected to take place in the
second quarter of 2018. Aerie is also focused on global expansion
and the development of additional product candidates and
technologies in ophthalmology.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the success, timing
and cost of our ongoing and anticipated preclinical studies and
clinical trials for our current product candidates, including
statements regarding the timing of initiation and completion of the
studies and trials; our expectations regarding the clinical
effectiveness of our product candidates and results of our clinical
trials; the timing of and our ability to request, obtain and
maintain FDA or other regulatory authority approval of, or other
action with respect to, our product candidates, including the
expected timing of, and timing of regulatory and/or other review
of, filings for our product candidates; our expectations regarding
the commercialization of our product candidates; the potential
advantages of our product candidates; our plans to pursue
development of our product candidates for additional indications
and other therapeutic opportunities; our plans to explore possible
uses of our existing proprietary compounds beyond glaucoma; our
ability to protect our proprietary technology and enforce our
intellectual property rights; and our expectations regarding
strategic operations, including our ability to in-license or
acquire additional ophthalmic products or product candidates or
technologies. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events, competitive
dynamics, industry change and other factors beyond our control, and
depend on regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). In particular, the receipt of the
PDUFA goal date notification and the FDA advisory committee’s vote
in favor of Rhopressa® do not constitute FDA approval of the
Rhopressa® NDA, and there can be no assurance that the FDA will
complete its review by the PDUFA goal date, that the FDA will not
require changes or additional data that must be made or received
before it will approve the NDA, if ever, or that the FDA will
approve the NDA. Forward-looking statements are not guarantees of
future performance and our actual results of operations, financial
condition and liquidity, and the development of the industry in
which we operate may differ materially from the forward-looking
statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204005034/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsInvestorsAmi Bavishi,
212-213-0006abavishi@burnsmc.comorMediaJustin Jackson,
212-213-0006jjackson@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024